AZ.Pharmabel SPRL
AZ.Pharmabel reported revenue of 966,662 € for the 2025 financial year (annual accounts filed with the NBB on 18 Feb 2026).
The score of AZ.Pharmabel shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +6 % Equity +183 % Total assets -4 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
AZ.Pharmabel's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 966,662 € | ||||
| Net result | 8,418 € | ||||
| Equity | 100,741 € | ||||
| Cash | 117,478 € | ||||
| EBITDA | 19,105 € | ||||
| Total assets | 479,564 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 18 Feb 2026
- Year ended 30 Jun 2024filed on 24 Mar 2025
- Year ended 30 Jun 2023filed on 08 Feb 2024
- Year ended 30 Jun 2022filed on 10 Feb 2023
- Year ended 30 Jun 2021filed on 07 Feb 2022
AZ.Pharmabel's financial analysis
- Solvency21.0%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of AZ.Pharmabel
AZ.Pharmabel's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0508.863.780
- VAT number
- BE0508863780
- Peppol
- Registered · 0208:0508863780 · as of 10 Nov 2026
- Legal form
- SPRL
- Incorporated
- 03 Jan 2013
- Registered office
- 1030 Schaerbeek
- Latest accounts
- 2025 · filed on 18 Feb 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
AZ.Pharmabel (SPRL) has been based in Schaerbeek since 2013, active in: retail sale of pharmaceutical products. For 2025, it reports revenue of 966,662 €, a net profit of 8,418 € and equity of 100,741 €. Its solvency stands at 21.0%, below the median of its sector (37.8%).
Companies similar to AZ.Pharmabel
Companies in the same business, of comparable size and area, outside its group.
- Biomedim Retail sale of pharmaceutical products Plombières · balance sheet 430,148 €
- Pharmacie DU Joncquois Retail sale of pharmaceutical products Mons · balance sheet 479,246 €
- Apotheek Thielen Retail sale of pharmaceutical products Sint-Gillis-Waas · balance sheet 470,532 €
- Paracelsus Retail sale of pharmaceutical products Aalst · balance sheet 413,042 €
- Farma Booischot Retail sale of pharmaceutical products Heist-op-den-Berg · balance sheet 558,918 €
- Pharmenform Retail sale of pharmaceutical products Koekelberg · balance sheet 567,837 €
- "Farminco" Retail sale of pharmaceutical products Andenne · balance sheet 589,804 €
- Vermunicht Retail sale of pharmaceutical products Hulshout · balance sheet 602,591 €
Frequently asked questions about AZ.Pharmabel
What is the revenue of AZ.Pharmabel?
According to the 2025 annual accounts filed with the NBB, the revenue of AZ.Pharmabel amounts to 966,662 €.
What is the VAT number of AZ.Pharmabel?
In Belgium, the VAT number is the company number prefixed with BE: BE0508863780 for AZ.Pharmabel, if the company is VAT-registered. Its company number (CBE) is 0508.863.780.
Where is the registered office of AZ.Pharmabel?
According to the CBE register, the registered office of AZ.Pharmabel is in 1030 Schaerbeek.
What is the equity of AZ.Pharmabel?
At the close of the 2025 financial year, the equity of AZ.Pharmabel amounts to 100,741 €, a solvency of 21.0% of total assets.
Who manages AZ.Pharmabel?
The register lists 1 active mandates at AZ.Pharmabel. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of AZ.Pharmabel
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →